# Evaluate the Pharmacokinetics of BAT2022 in Healthy Chinese Subjects

> **NCT05518695** · PHASE1 · COMPLETED · sponsor: **Bio-Thera Solutions** · enrollment: 32 (actual)

## Conditions studied

- SARS-CoV-2 Infection

## Interventions

- **DRUG:** BAT2022

## Key facts

- **NCT ID:** NCT05518695
- **Lead sponsor:** Bio-Thera Solutions
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-09
- **Primary completion:** 2022-11-07
- **Final completion:** 2022-11-07
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2022-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05518695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05518695, "Evaluate the Pharmacokinetics of BAT2022 in Healthy Chinese Subjects". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT05518695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*